To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, conducted its first-ever pharmacy survey during the second quarter of 2016.
When is retail right? Consider these four benefits that will impact the bottom line.
HHS finalized ClinicalTrial.gov rules encourage healthcare improvement and public benefit by increasing transparency and accountability across the industry.
Expert offers specific actions for managed care execs to take
A new study shows that many adults with depression don’t receive treatment, whereas others receive treatments that do not match their level of illness severity.
Nationwide class action suit spurs new coverage decision for hepatitis C medications.
A new database helps payers understand which genetic tests are available, which genes they test for, and which tests would be appropriate to use to inform patient management.
A new study highlights why vaccination costs should be a top consideration when evaluating benefit offerings.
Study shows that an integrated pharmacy approach with community mental health centers produces higher adherence rates and lower overall healthcare costs.
Where do the capabilities of healthcare technology end and the need for the human hand begin to deliver top value for managed care executives?
Early planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.
Technology in pharmacy is leading to improved safety, accountability, and efficiency.
The opioid crisis in the U.S. is a multidimensional problem requiring a multistakeholder solution.
This model, touted as “next-generation,” combines retail and specialty and mail services and PBM along with immediate care clinics.
Managed Healthcare Executive recently invited a panel of experts representing different sectors of the healthcare industry to explore specialty pharmaceutical challenges and identify potential solutions.
There are promising developments in the pipeline for patients with treatment-resistant depression.
Managed Healthcare Executive conducted its first-ever managed care pharmacy survey during the second quarter of 2016 in partnership with Access Market Intelligence. Here’s a look at some of the key findings, with experts weighing in on the results.
Rising drug costs are a big problem for all healthcare systems in the U.S. Here’s how three hospitals are addressing the problem.
Expert: Expectations are high that biosimilars can control overall biologic cost growth.
Executives need to ask themselves four key questions to mitigate the negative impact of rising drug costs.
Systematic review provides comprehensive first look at TNF-alpha biosimilar treatments.
As ACOs continue to grow in the healthcare sector, it is imperative that a liaison is in place to act as an intermediary between ACO members and patients to help achieve desired outcomes.
Experts break down the controversy over the agency’s release of Overall Hospital Quality Star Ratings.
Obesity and associated comorbidities strain the healthcare system, so why has R&D for new weight loss medications been lackluster?
Surveys conducted by the AACE with support from Sanofi US, identified differences in perceptions among adults living with type 2 diabetes. What healthcare professionals don't know may surprise you.
